DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4

Completed

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Lorlatinib

First Posted Date: 2020-09-09

Last Posted Date: 2024-12-20

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT04541706

Locations: 🇮🇳
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India
🇮🇳
The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
🇮🇳
Apex Wellness Hospital, Nashik, Maharashtra, India

and more 9 locations

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

Phase 1

Completed

Conditions: Viral Disease

Interventions: Drug: PF-07304814
Drug: Placebo

First Posted Date: 2020-09-01

Last Posted Date: 2023-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT04535167

Locations: 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸
Massachusetts General Hospital Translational and Clinical Research Center, Boston, Massachusetts, United States
🇧🇪
University Hospital Brugmann, Brussels, Belgium

and more 10 locations

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13-valent pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine

First Posted Date: 2020-08-28

Last Posted Date: 2023-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 668

Registration Number: NCT04530838

Locations: 🇯🇵
Inami Pediatrics, Setagaya-ku, Tokyo, Japan
🇯🇵
Saitoh-Clinic, Nishitokyo-shi, Tokyo, Japan
🇯🇵
Futaba Clinic, Shinjuku-ku, Tokyo, Japan

and more 35 locations

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Other: Saline
Biological: Influenza vaccine

First Posted Date: 2020-08-26

Last Posted Date: 2022-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 1796

Registration Number: NCT04526574

Locations: 🇺🇸
Indago Research and Health Center, Inc., Hialeah, Florida, United States
🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸
East Valley Gastroenterology and Hepatology Associates, Chandler, Arizona, United States

and more 50 locations

Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

Completed

Conditions: Psoriatic Arthritis

First Posted Date: 2020-08-18

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 116

Registration Number: NCT04517669

Locations: 🇮🇱
Hadassah University Hospital - Ein Kerem, Jerusalem, Israel
🇮🇱
Hadassah Hebrew University Medical Center - Ein Kerem, Jerusalem, Israel
🇮🇱
Meir Medical Center, Kfar- Sava, Israel

and more 47 locations

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

Phase 2

Terminated

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600
Drug: Placebo

First Posted Date: 2020-08-18

Last Posted Date: 2024-06-18

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT04517864

Locations: 🇺🇸
Stony Brook Dermatology, Stony Brook, New York, United States
🇨🇦
Lynderm Research Inc., Markham, Ontario, Canada
🇺🇸
Marvel Clinical Research 002, LLC, Huntington Beach, California, United States

and more 36 locations

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

Phase 2

Completed

Conditions: Hyperlipidemias
Dyslipidemias
Hyperlipoproteinemias

Interventions: Drug: Placebo
Drug: Vupanorsen

First Posted Date: 2020-08-18

Last Posted Date: 2022-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 286

Registration Number: NCT04516291

Locations: 🇺🇸
Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States
🇨🇦
GNMI MRI and CT Medical Imaging, Mississauga, Ontario, Canada
🇨🇦
Aggarwal and Associates Limited, Brampton, Ontario, Canada

and more 109 locations

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Phase 4

Completed

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Drug: Dacomitinib

First Posted Date: 2020-08-13

Last Posted Date: 2024-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT04511533

Locations: 🇮🇳
Artemis hospital, Gurugram, Haryana, India
🇮🇳
Apex Wellness Hospital, Nashik, Maharashtra, India
🇮🇳
Gujarat Hospital - Gastro & Vascular Centre, Surat, Gujarat, India

and more 12 locations

Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Etanercept

First Posted Date: 2020-08-11

Last Posted Date: 2021-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 763

Registration Number: NCT04507763

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Completed

Conditions: Spondyloarthrosis

Interventions: Drug: Etanercept

First Posted Date: 2020-08-11

Last Posted Date: 2021-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 763

Registration Number: NCT04507776

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy